Associated Papers
TP53 mutation predict poor prognosis in diffuse large B-cell lymphoma: a single-center study.
Zhang H et al.
Annals of Hematology, 2026
Identification of high-risk signatures and therapeutic targets through molecular characterization and immune profiling of TP53-mutant breast cancer.
Paulino PJIV et al.
Journal, Genetic Engineering & Biotechnology, 2025
TP53 Mutation Status in Myelodysplastic Neoplasm and Acute Myeloid Leukemia: Impact of Reclassification Based on the 5th WHO and International Consensus Classification Criteria: A Korean Multicenter Study.
Kim HY et al.
Annals of Laboratory Medicine, 2025
Prevalence of Molecular Alterations in a Swiss Cohort of 512 Colorectal Carcinoma Patients by Targeted Next-Generation Sequencing Analysis in Routine Diagnostics.
Haefliger S et al.
Pathobiology : Journal of Immunopathology, Molecular and Cellular Biology, 2023
Long non‑coding RNAs interact with RNA‑binding proteins to regulate genomic instability in cancer cells (Review).
Yang K et al.
Oncology Reports, 2022
Landscape of somatic alterations in large-scale solid tumors from an Asian population.
Wu L et al.
Nature Communications, 2022
Upfront Next Generation Sequencing in Non-Small Cell Lung Cancer.
Kuang S et al.
Current Oncology (toronto, Ont.), 2022
Soft Tissue Sarcoma Study: Association of Genetic Alterations in the Apoptosis Pathways with Chemoresistance to Doxorubicin.
Kirilin EM et al.
Cancers, 2022
Mechanistic insight into the destabilization of p53TD tetramer by cancer-related R337H mutation: a molecular dynamics study.
Yu Y et al.
Physical Chemistry Chemical Physics : Pccp, 2022
Driver mutations of intrahepatic cholangiocarcinoma shape clinically relevant genomic clusters with distinct molecular features and therapeutic vulnerabilities.
Wang XY et al.
Theranostics, 2022
Clinicopathological and genomic features in patients with head and neck neuroendocrine carcinoma.
Ohmoto A et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc, 2021
Germline variants in hereditary breast cancer genes are associated with early age at diagnosis and family history in Guatemalan breast cancer.
Ren M et al.
Breast Cancer Research and Treatment, 2021
Analysis and Interpretation of the Impact of Missense Variants in Cancer.
Petrosino M et al.
International Journal of Molecular Sciences, 2021
Improved Variant Detection in Clinical Myeloid NGS Testing by Supplementing a Commercial Myeloid NGS Assay with Custom or Extended Data Filtering and Accessory Fragment Analysis.
Schejbel L et al.
Molecular Diagnosis & Therapy, 2021
p53 tetramerization: at the center of the dominant-negative effect of mutant p53.
Gencel-Augusto J et al.
Genes & Development, 2020
The tetramerization domain of the tree shrew p53 protein displays unique thermostability despite sharing high sequence identity with the human p53 protein.
Nakagawa N et al.
Biochemical and Biophysical Research Communications, 2020
Elevated telomere dysfunction in cells containing the African-centric Pro47Ser cancer-risk variant of TP53.
Tutton S et al.
Oncotarget, 2019
Finding driver mutations in cancer: Elucidating the role of background mutational processes.
Brown AL et al.
Plos Computational Biology, 2019
DNA methylation-based reclassification of olfactory neuroblastoma.
Capper D et al.
Acta Neuropathologica, 2018
Endogenous Leu332Gln mutation in p53 disrupts the tetramerization ability in a canine mammary gland tumor cell line.
Ochiai K et al.
Oncology Reports, 2018
p53 oligomerization status modulates cell fate decisions between growth, arrest and apoptosis.
Fischer NW et al.
Cell Cycle (georgetown, Tex.), 2016
Mutant p53 and mTOR/PKM2 regulation in cancer cells.
Dando I et al.
Iubmb Life, 2016
Two p53 tetramers bind one consensus DNA response element.
Kearns S et al.
Nucleic Acids Research, 2016
Landscape of somatic mutations in 560 breast cancer whole-genome sequences.
Nik-Zainal S et al.
Nature, 2016
Mutational landscape of intrahepatic cholangiocarcinoma.
Zou S et al.
Nature Communications, 2014
Proteome-wide analysis of human disease mutations in short linear motifs: neglected players in cancer?
Uyar B et al.
Molecular Biosystems, 2014
TP53 mutations in human cancer: database reassessment and prospects for the next decade.
Leroy B et al.
Human Mutation, 2014
Identification of molecular pathway aberrations in uterine serous carcinoma by genome-wide analyses.
Kuhn E et al.
Journal of the National Cancer Institute, 2012
Transactivation and reactivation capabilities of temperature-dependent p53 mutants in yeast and human cells.
Jagosova J et al.
International Journal of Oncology, 2012
Cancer-associated p53 tetramerization domain mutants: quantitative analysis reveals a low threshold for tumor suppressor inactivation.
Kamada R et al.
The Journal of Biological Chemistry, 2011
Insight into the structural basis of pro- and antiapoptotic p53 modulation by ASPP proteins.
Ahn J et al.
The Journal of Biological Chemistry, 2009
Evaluation of transcriptional activity of p53 in individual living mammalian cells.
Imagawa T et al.
Analytical Biochemistry, 2009
Dimerization of the core domain of the p53 family: a computational study.
Madhumalar A et al.
Cell Cycle (georgetown, Tex.), 2009
Molecular basis of Pirh2-mediated p53 ubiquitylation.
Sheng Y et al.
Nature Structural & Molecular Biology, 2008
Influence of tetramerisation on site-specific post-translational modifications of p53: comparison of human and murine p53 tumor suppressor protein.
Warnock LJ et al.
Cancer Biology & Therapy, 2008
Noncanonical DNA motifs as transactivation targets by wild type and mutant p53.
Jordan JJ et al.
Plos Genetics, 2008
Detailed mapping of chromosome 17p deletions reveals HIC1 as a novel tumor suppressor gene candidate telomeric to TP53 in diffuse large B-cell lymphoma.
Stöcklein H et al.
Oncogene, 2008
Analysis of transactivation capability and conformation of p53 temperature-dependent mutants and their reactivation by amifostine in yeast.
Grochova D et al.
Oncogene, 2008
The conserved CPH domains of Cul7 and PARC are protein-protein interaction modules that bind the tetramerization domain of p53.
Kaustov L et al.
The Journal of Biological Chemistry, 2007
Tandem dimerization of the human p53 tetramerization domain stabilizes a primary dimer intermediate and dramatically enhances its oligomeric stability.
Poon GM et al.
Journal of Molecular Biology, 2007
The relationship among p53 oligomer formation, structure and transcriptional activity using a comprehensive missense mutation library.
Kawaguchi T et al.
Oncogene, 2005
Role of phosphorylation in p53 acetylation and PAb421 epitope recognition in baculoviral and mammalian expressed proteins.
Warnock LJ et al.
The Febs Journal, 2005
Restoration of wild-type conformation to full-length and truncated p53 proteins: specific effects of ATP and ADP.
Warnock LJ et al.
Cancer Biology & Therapy, 2004
A stable human p53 heterotetramer based on constructive charge interactions within the tetramerization domain.
Brokx RD et al.
The Journal of Biological Chemistry, 2003
Effect of wild-type, S15D and R175H p53 proteins on DNA end joining in vitro: potential mechanism of DNA double-strand break repair modulation.
Okorokov AL et al.
Carcinogenesis, 2002
Latent and active p53 are identical in conformation.
Ayed A et al.
Nature Structural Biology, 2001
Structure and functionality of a designed p53 dimer.
Davison TS et al.
Journal of Molecular Biology, 2001
Assignment of 1H(N), 15N, 13C(alpha), 13CO and 13C(beta) resonances in a 67 kDa p53 dimer using 4D-TROSY NMR spectroscopy.
Mulder FA et al.
Journal of Biomolecular Nmr, 2000
Longitudinal profiling of IDH-mutant astrocytomas reveals acquired RAS-MAPK pathway mutations associated with inferior survival.
Rodriguez Almaraz E et al.
Neuro-oncology Advances, 0